Press release
mivenion GmbH and PTB Berlin report patent grants for imaging of inflammation
mivenion GmbH announces that it has secured patent protection for its key technology of optical imaging of inflammation. The patent rights covering diagnostic technologies for the optical rheumatoid arthritis imaging were exclusively licensed from the Physikalisch-Technische Bundesanstalt (PTB Berlin). Now, mivenion and PTB Berlin have been granted its patent by the U.S. Patent and Trademark Office in February 2011, followed by a grant by the European Patent Office in December 2011. The scope of the granted patent claims is on methods, devices and near infrared fluorescence dyes for imaging of inflammation in the joints.“We are very delighted about this important achievement”, stated Kai Licha, head of R&D and responsible for patents. “The patent protection for this key technology strengthens our ongoing expansion into the major markets, increasingly beyond Germany, where the current installation base of more than 25 Xiralite® devices already demonstrates the great acceptance of the Rheumascan procedure”.
Fluorescence optical imaging using mivenion´s Xiralite® camera system is now clinically proven to yield indispensible diagnostic information in a variety of inflammatory and degenerative joint diseases. Sensitivity, easy use, quantitative imaging analysis, and high patient acceptance are unique features of the Xiralite fluorescence camera system, thereby significantly broadening the spectrum of diagnostic capabilities for diagnosis of inflammatory joint diseases. Following successful market approval for Xiralite® in the EU, mivenion is now preparing for the entry into US market in 2012.
mivenion GmbH is a life-science company focusing on personalized medicine for patients with inflammatory and autoimmune diseases. With its strong expertise in both pharmaceuticals and medical devices, mivenion is providing cutting edge solutions for life-long patient care. mivenion’s medical solutions encompass innovative diagnostic imaging and provide evidence on treatment outcome. Xiralite, the leading product of mivenion, enables the Rheumascan procedure. It provides for the first time an integrated solution for patients with inflammatory diseases in the hands. Based on optical technologies, active inflammation is diagnosed at a very early stage with confidence, attractive technical ease, and high patient comfort.
Press contact:
Dr. Michael Schirner
Robert-Koch-Platz 4
10115 Berlin
Germany
phone: +49 30 688379220
schirner@mivenion.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release mivenion GmbH and PTB Berlin report patent grants for imaging of inflammation here
News-ID: 206303 • Views: …
More Releases from mivenion GmbH
mivenion receives market authorization for Xiralite® in Canada
Fluorescence optical imaging (FOI) with the Xiralite® fluorescence imaging system X4 is a sensitive and safe medical procedure for visualization of altered microcirculation in the hands in early and late stages of different diseases such as rheumatoid arthritis, psoriatic arthritis, scleroderma, osteoarthritis or Raynaud’s syndrom. Xiralite® is CE marked and already established in five European countries. The whole procedure is highly standardized, very sensitive, fast, and convenient for the patients.…
mivenion announces 4 abstracts for fluorescence optical imaging using the Xirali …
Highlights include:
• ICG-enhanced fluorescence optical imaging (FOI) is able to detect typical inflammatory changes in subjects with arthralgia and psoriasis prior to signs of clinically established arthritis. The detection of typical inflammatory changes in subjects with cutaneous manifestations of psoriasis or family history of psoriasis and joint pain but without clinical signs of synovitis or tendinitis suggests that a non-arthritic, subclinical disease stage may precede the onset of clinically active…
mivenion to establish Rheumascan at Karolinska Institutet, Stockholm, Sweden
About 5% of the patients attending primary care physicians intermittently suffer from swelling and tenderness of the hand joints. In many cases, inflammatory joint diseases such as rheumatoid arthritis or psoriatic arthritis are the main cause of the disease symptoms and, without treatment, may lead to poor outcome and lifelong suffering. In recent years there is increasing evidence that early diagnosis and treatment of arthritis may effectively stop the progression…
mivenion receives ISO 13485 certification for Xiralite® manufacturing and distr …
mivenion has received the official ISO 13485:2003 + AC:2009 certification as a medical device manufacturer. Published in 2003, the ISO 13485 standard outlines the requirements for a comprehensive quality management system for all aspects of the design and manufacturing process for medical devices. The certification covers the design, development, manufacturing, and distribution of the patented Xiralite® fluorescence camera system and its XiraView® software.
“We are delighted that we can announce…
More Releases for Xiralite
mivenion receives market authorization for Xiralite® in Canada
Fluorescence optical imaging (FOI) with the Xiralite® fluorescence imaging system X4 is a sensitive and safe medical procedure for visualization of altered microcirculation in the hands in early and late stages of different diseases such as rheumatoid arthritis, psoriatic arthritis, scleroderma, osteoarthritis or Raynaud’s syndrom. Xiralite® is CE marked and already established in five European countries. The whole procedure is highly standardized, very sensitive, fast, and convenient for the patients.…
mivenion announces 4 abstracts for fluorescence optical imaging using the Xirali …
Highlights include:
• ICG-enhanced fluorescence optical imaging (FOI) is able to detect typical inflammatory changes in subjects with arthralgia and psoriasis prior to signs of clinically established arthritis. The detection of typical inflammatory changes in subjects with cutaneous manifestations of psoriasis or family history of psoriasis and joint pain but without clinical signs of synovitis or tendinitis suggests that a non-arthritic, subclinical disease stage may precede the onset of clinically active…
mivenion to establish Rheumascan at Karolinska Institutet, Stockholm, Sweden
About 5% of the patients attending primary care physicians intermittently suffer from swelling and tenderness of the hand joints. In many cases, inflammatory joint diseases such as rheumatoid arthritis or psoriatic arthritis are the main cause of the disease symptoms and, without treatment, may lead to poor outcome and lifelong suffering. In recent years there is increasing evidence that early diagnosis and treatment of arthritis may effectively stop the progression…
mivenion receives ISO 13485 certification for Xiralite® manufacturing and distr …
mivenion has received the official ISO 13485:2003 + AC:2009 certification as a medical device manufacturer. Published in 2003, the ISO 13485 standard outlines the requirements for a comprehensive quality management system for all aspects of the design and manufacturing process for medical devices. The certification covers the design, development, manufacturing, and distribution of the patented Xiralite® fluorescence camera system and its XiraView® software.
“We are delighted that we can announce…
mivenion targets musculoskeletal imaging experts at ECR 2011
mivenion GmbH, the leading company in optical imaging of arthritis, will exhibit its groundbreaking Rheumascan workstation Xiralite® X4 and the most advanced XiraView 3.6 software for diagnostic imaging of inflammation in the hands at the forthcoming annual European Congress of Radiology (ECR) in Vienna, Austria, March 4-7. The ECR is one of the largest medical meetings worldwide and the second largest radiological congress, with around 19,000 participants from…
